A 2022 clinical study found that an injectable GLP-1 agonist given during IBS flare-ups significantly reduced pain intensity compared to placebo twice as many patients achieved meaningful pain relief with the GLP-1 analog than with placebo
Weakness in the hand, especially when gripping or pinching
10.3389/fphar.2022.925377 33 ZhouY.ChenM.LiuL.ChenZ
Psychiatry 22 , 13761384 (2017)
GLP-1-1 GLP-1 1
Modifications to the peptide chain to reduce degradation by DPP-4, combined with acylation to promote non-covalent binding to albumin, resulted in long-acting formulations, enabling their use in clinical practice.3,5 Initially, GLP-1 receptor monoagonists were marketed with the aim of treating type 2 diabetes, harnessing their incretin effect and glucose-dependent mechanism, along with their capacity to reduce body weight and their beneficial effects on associated comorbidities.1,3,5 Subsequently, research shifted its focus to obesity, employing higher doses than those used for diabetes.3,5 This was followed by the development of unimolecular structures with multi-receptor activity, such as GIP/GLP-1 and GLP-1/glucagon (GCG) coagonists, as well as GIP/GLP-1/GCG triagonists
